Risk factors

GRAIL (GRAL) risk factors

Item 1A of every GRAIL, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open GRAL in Gloom →
GRAIL's chart, financials and news, free in your browser.Open GRAL in Gloom →
  • FY2025 10-K risk factors
    67 risks10 new10 dropped20 reworded

    The failed NHS-Galleri trial endpoints dominate new disclosures, threatening commercial adoption, reimbursement, and stock price stability.

    Filed Mar 12, 2026
  • FY2024 10-K risk factors
    67 risks

    Grail faces massive net losses, reaching $2.0 billion in fiscal 2024, driven by research and commercialization of its Galleri cancer test.

    Filed Mar 05, 2025